Andecaliximab
GS-US-395-1663
Phase 2 small_molecule terminated
Quick answer
Andecaliximab for Crohn's Disease is a Phase 2 program (small_molecule) at Gilead Sciences Ireland UC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Gilead Sciences Ireland UC
- Indication
- Crohn's Disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated